EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers

Justin A Shapiro, Nathan J Dupper, Breena Fraga-Walton, Andrew T Bockus iD, Siegfried S F Leung, Kai Yang, Chinmay Bhatt, Megan K DeMart, Miguel P Baldomero, Luis Hernandez, Gabriel Fung, Sammy Metobo und 24 weitere

Journal of Medicinal Chemistry · 12.03.2026 · 69 (5) · 5441-5460

DOI: 10.1021/acs.jmedchem.5c02445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.02.2026. Verfasst von Justin A Shapiro und 35 weiteren Autor:innen. Beteiligte Einrichtung: Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Cyclin A, Cyclin B, Antineoplastic Agents, E2F Transcription Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High Resolution Image Download MS PowerPoint Slide Cyclins A and B bind and activate their cognate cyclin-dependent kinase (CDK) to regulate progression through the S and G2/M phases of the cell cycle, respectively. Cyclins recruit substrates and regulators through the binding of an RxL motif with a Hydrophobic Patch (HP) on the cyclin surface. We recently disclosed the first class of passively permeable macrocyclic peptides that bind to the HP of both Cyclin A and Cyclin B and selectively kill cancer cells with high E2F activity. We used a lead example to demonstrate in vivo tumor regression in cell-line-derived xenograft models of small-cell lung cancer (SCLC) via intraperitoneal dosing. Here we describe the optimization of this series for drug-like properties and oral bioavailability, resulting in the discovery of a lead compound, which demonstrates tumor regression in CDX models of SCLC via oral dosing. We are currently evaluating Cyclin A/B inhibition in a Phase 1 clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin ACyclin BAntineoplastic AgentsE2F Transcription FactorsG1 Phase Cell Cycle CheckpointsPeptides, CyclicMacrocyclic CompoundsHumansAnimalsAdministration, OralBiological AvailabilityMiceCell Line, TumorStructure-Activity RelationshipS Phase Cell Cycle Checkpoints

Substanzen

Cyclin ACyclin BAntineoplastic AgentsE2F Transcription FactorsPeptides, CyclicMacrocyclic Compounds

Autor:innen und Institutionen

  • Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States.

ORCID-Profile: Andrew T Bockus, James B Aggen

Zitieren

APA

Shapiro, J. A., Dupper, N. J., Fraga-Walton, B., Bockus, A. T., Leung, S. S. F., Yang, K., Bhatt, C., DeMart, M. K., Baldomero, M. P., Hernandez, L., Fung, G., Metobo, S., Xie, S., Lent, B. M., Spellmeyer, D. C., Luna, J., Hoang, D., Chand, M., Gritsenko, Y., …, & Aggen, J. B. (2026). Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers. Journal of Medicinal Chemistry, 69(5), 5441-5460. https://doi.org/10.1021/acs.jmedchem.5c02445

Vancouver

Shapiro JA, Dupper NJ, Fraga-Walton B, Bockus AT, Leung SSF, Yang K, et al. Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers. Journal of Medicinal Chemistry. 2026;69(5):5441-5460. doi:10.1021/acs.jmedchem.5c02445

BibTeX
@article{Shapiro2026,
  author = {Shapiro, Justin A and Dupper, Nathan J and Fraga-Walton, Breena and Bockus, Andrew T and Leung, Siegfried S F and Yang, Kai and Bhatt, Chinmay and DeMart, Megan K and Baldomero, Miguel P and Hernandez, Luis and Fung, Gabriel and Metobo, Sammy and Xie, Steven and Lent, Bryan M and Spellmeyer, David C and Luna, Joshua and Hoang, Dalena and Chand, Manesh and Gritsenko, Yuliana and Gleason, Catherine E and Hamkins-Indik, Frances and Zheng, Jie and Odeh, Ranya and Nosrati, Meisam and He, Daphne and Bambal, Ramesh and Cremin, Peadar and Fang, Jinshu and Levin, Bernard and Wang, Evelyn W and Evangelista, Marie and Earp, David and Kreatsoulas, Constantine and Singh, Rajinder and Garcia, Pablo D and Aggen, James B},
  title = {Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {5},
  pages = {5441--5460},
  doi = {10.1021/acs.jmedchem.5c02445}
}
Kostenlos starten →